The S6K1 inhibitor PF-4708671 was particularly effective in reducing cell migration of PC3 and DU145 cell lines, suggesting that it could represent a possible adjuvant to prevent prostate cancer progression to its advanced state. Here, RPS6KB1 is linked to prostate cancer.